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Abstract Milk proteins have attracted extensive interest in terms of their bioavailability
following ingestion. Enzymatic digestion of dairy products generates numerous peptides
with various biological activities. Both human milk and infant formulas based on cow's
milk are potential sources of bioactive peptides. This review aims to present current
knowledge on the formation and fate of bioactive peptides from milk feeds intended for
infants. Emphasis is placed on the source of the bioactive peptides with the nutritional
impact of human milk and cow milk-based formulas on infant health being critically
discussed from that perspective. Furthermore, the effect of processing and in vitro or
in vivo digestion on the release and availability of peptides with bioactive sequences is
evaluated. Considerable differences with respect to bioavailability and metabolic effects
between the biologically active fragments generated following ingestion of human milk
and infant formulas are documented. Peptides from milk protein of bovine origin could
be a valuable supplement to human milk as multiple health-promoting properties are
attributed to peptide fractions identified in standard cow milk-based infant formulas.
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1 Introduction
Milk is very often described as the “ultimate” food which fulfills the nutritional needs
of the mammal newborn and ensures safe development and growth during the first
stages of its life (Mills et al. 2011). Individual milk components contribute to the high
biological and nourishing value of this food. Milk proteins, for instance, are known to
exert various actions that promote human health. These actions include stimulation of
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the immune system, digestion and absorption of nutritional elements, development of
endogenous defense mechanisms against bacteria, fungi and viruses, prebiotic effects,
and others (Lönnerdal 2003).
Recently, milk proteins have attracted extensive interest in terms of their bioavailabil-
ity following ingestion. In vivo digestion of milk proteins within the gastrointestinal tract
results in the release of peptides with new biological properties compared to the ones
exhibited by the intact, precursor molecule (Chatterton et al. 2004). Many of these protein
fragments, also known as bioactive peptides, consist of approximately 3–20 amino acids,
which are encrypted within the parental protein and become activated following their
release, induced by the action of gastric and pancreatic enzymes (Kekkonen 2009;
Korhonen 2009). In addition, biologically active peptides may be formed during food
processing. In vitro hydrolysis of milk proteins is a common method for producing
hydrolyzed peptide fragments used for hypoallergenic infant formulas (Korhonen et al.
1998). The peptides generated either in vitro or in vivo differ markedly with respect to
their biological activities depending on the digestion process and/or the parental protein
from which they are released.
The identification of bioactive milk peptides was first reported in 1950 (Mellander
1950). Since then, numerous reports document the presence of peptides which exert some
physiological effect on the human body in milk or milk-based products (Beaulieu et al.
2007; Foltz et al. 2007; Haque et al. 2009; Hayes et al. 2006; Kamau et al. 2010; LeBlanc
et al. 2002; Meisel and Fitzgerald 2000; Nagpal et al. 2011). However, to the best of our
knowledge, limited studies exist which focus on the health-promoting properties of milk
peptides detected in infant feeding regimens. This paper reviews recent research on the
formation and fate of bioactive peptides frommilk feeds intended for infants. Furthermore,
suggestions based on recently published research for improvement of the nutritional value
of infant formulas through the inclusion of milk-derived peptides serving as functional
ingredients are provided.
2 Human milk versus infant formula as a potential source of bioactive peptides
Human milk is considered the reference standard for the manufacture of infant formulas.
Thus, the latter are designed to simulate the content and the performance of the former in
an attempt tomimic the effect of breast milk onmetabolic and other physiologic functions.
In addition to standard formulas, hydrolysates of cows' milk are also available for infant
nutrition usually supplied as a hypoallergenic therapeutic or preventive formulation for
allergenized or sensitized newborns (Caffarelli et al. 2002).
Qualitative and quantitative differences exist between humanmilk and infant formulas,
and these include protein compositional dissimilarities. For instance, cows' milk-based
infant formulas contain three to four times higher protein content compared to human
milk (Rudloff and Kunz 1997). Furthermore, caseins dominate the protein fraction in
bovine milk (∼80%), whereas the principal class of protein in human milk is whey,
particularly during the first days of lactation (Kunz and Lönnerdal 1989; Kunz and
Lönnerdal 1990). Proteomic analysis indicates that human milk does not contain β-
lactoglobulin and αs2-casein, whereas lactoferrin and α-lactalbumin are the main protein
components (Armaforte et al. 2010). The same study provides further evidence on
qualitative similarities in terms of the protein profile of infant formula and bovine milk
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with αs1-casein, αs2-casein, β-casein, and β-lactoglobulin being the most abundant
proteins. Other major differences between human and bovine milk proteins such as the
different glycosylation degree of immunoglobulins, lactoferrin, and casein have been
documented (Nwosu et al. 2012).
Considering human milk as the gold standard, several attempts have been made to
“humanize” infant formulas. Commercially available products include whey-enriched
infants formulas based on cow's milk. In this case, formulations include a casein-to-whey
protein ratio of approximately 40:60, which is somewhat closer to the one encountered in
human milk. Whey-dominant formulas which resemble the human milk compositional
standard seem to a have the same impact on growth of premature infants as compared to
casein-dominant formulations (Bernbaum et al. 1989). However, other advantages par-
ticularly for low-birth weight and preterm infants may be related to whey-dominant
formulas, which is an expected finding as milk is a biological fluid that has evolved to
meet the nutritional demands of the human species (Rudloff and Kunz 1997). Other
attempts to narrow the gap between the protein content of human milk and infant
formulas involve the fortification of infant formulas with purified proteins of bovine
origin, which are abundant in human milk such as α-lactalbumin, lactoferrin, and others
(Chatterton et al. 2004).
Despite the efforts to replicate the protein compositional recipe of human milk, infant
formulas and protein hydrolysate products display qualitative and quantitative differences
in terms of protein content that may affect physiological process in the newborn. In
general, formulas provide a different profile of amino acids in addition to more protein
content. Differences in the parental (intact) proteins result most likely in the generation of
peptides with different biological activities following the process of digestion. It has been
documented that hydrolysis products of the native human α-caseins generated by the
proteolytic activity of plasmin cannot be detected in commercial formulations intended
for infants (Armaforte et al. 2010). This is because bovine plasmin preferentially acts
uponβ-casein (Fox andKelly 2005). As a result, considerable differences are expected in
terms of bioavailability and metabolic effects between the biologically active fragments
generated following ingestion of human milk, infant formulas, and hydrolyzed products,
which may affect infant growth.
3 Aspects of in vivo and in vitro generation of bioactive peptides
There are various ways for releasing bioactive peptides. First, milk proteins may be
digested in vitro during food processing by maturation with selected enzymes. In this
case, where milk is fermented with a proteolytic culture, the process is carefully con-
trolled (enzyme specificity, temperature, incubation time, etc.), and thus the release of
bioactive peptides may be predicted (Exl 2001). Common enzymes in the commercial
production of bioactive peptides via in vitro digestion include pepsin, trypsin, and
chymotrypsin (Korhonen et al. 1998). Bioactive peptides may also be generated follow-
ing ingestion in vivo by either digestive enzymes or by microbial enzymes (Kekkonen
2009). Thus milk proteins during their passage through the digestive system may be the
target of enzymes produced either by the human body or by microorganisms which
normally inhabit the gastrointestinal tract. A wide range of enzymes with different
cleavage sites may act throughout the whole gastrointestinal tract and under conditions
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which may differ depending on various physiological factors (Antalis et al. 2007). In this
case, the process is far less easy to control and to monitor. This is the reason why in vitro
digestion, also known as simulated gastrointestinal digestion (SGID), is often employed
to investigate the stability of milk proteins and the fate of bioactive peptides. SGID takes
into account key factors affecting the digestion process such as the rates of gastric
emptying, which are used to determine the period of incubation with gastric proteases,
and changes in gastric pH value which determine to a large extent the enzyme activity
(De Noni 2008).
Nevertheless, SGID may be regarded as an oversimplified method to determine the
fate of precursor milk proteins. In reality, things are more complicated as physiological
processes in vivo are not static, and the environment within the gastrointestinal tract of
an infant is subject to changes with time or cause. Gastric pH, for instance, is known to
be high in early neonatal life and has been determined to be 6.0 in term newborn infants
with the tendency to decrease sharply during the first 24 h of life (Widstrom et al. 1988).
According to Chatterton et al. (2004), proteins in human milk and infant formula
showed a pH-dependent extent of hydrolysis when incubated with gastric juice in a
pH range between 6.5 and 2.0. This is somewhat expected as gastric enzymes show
optimum activity at specific pH values. Furthermore, the concentration ofmilk proteases
(e.g., plasmin) present in breast milk is increased for premature infants, which results in
extensive hydrolysis of milk proteins to facilitate the digestion process (Armaforte et al.
2010). This could in turn affect the biological activity of the digests, as peptides have to
be absorbed from the intestine and reach their target cells in adequate concentrations. As
a result, one may conclude that the digestion process of milk proteins in vivo is a
complex process and depends on various factors which cannot be adequately simulated
in vitro. In vivo studies are more reliable in order to draw safe conclusions with respect
to the formation of bioactive peptides following the ingestion of human milk and infant
formulas. The formation of bioactive peptides in vivo following the digestion of milk
proteins has been documented in the past both in human (Boutrou et al. 2013; Foltz et al.
2007) and animal (Bouzerzour et al. 2012) models. According to these studies, although
evidence exists to support their presence in the human and piglet gastrointestinal tract,
further research is required to investigate the physiologic conditions which would allow
the bioactive peptides to exert their bioactivity.
4 Bioactive peptides in human milk and infant formulas
Peptides released from in vivo or in vitro digestion of milk proteins are known to affect
major systems such as the cardiovascular, nervous, digestive, and immune system.
According to Hayes et al. (2007), bioactive peptides from milk having a physiological
impact on human body can be categorized as antihypertensive, antithrombotic, opioid,
casein phosphopeptides, antimicrobial, cytomodulatory, immunomodulatory, and mis-
cellaneous. Recent findings indicate that milk peptides can have additional physiolog-
ical effects such as antioxidant activity or may even possess functional significance
which is not yet clearly understood. Therefore, the consideration of milk peptides as
dietary supplements or food additives could be promising for the food industry in the
future. Table 1 summarizes the bioactive peptides identified in both human and bovine
milk with potential beneficial effect on human health.
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4.1 Effects on the cardiovascular system
The release of angiotensin converting enzymes (ACE)-inhibitory peptides by SGID of
infant formulas has been documented by Hernández-Ledesma et al. (2004). According to
this study, enzymatically hydrolyzed casein and whey formulas exhibited higher ACE-
inhibitory activities than non-hydrolyzed milk protein formulations. It was hypothesized
that lowmolecular weight peptides (<3,000 Da) were mainly responsible for this activity
with several potent peptides being identified (β-Lg: RVYand LVR; β-casein: YPFPGPI
and HLPLP). The size of the hydrolyzed fragments could be critical in terms of the
antihypertensive activity as di- and tripeptides are easily absorbed in the intestine and
may reach the blood and other target sites (Hara et al. 1984). Furthermore, SGID had a




Fragment Peptide sequence Origin Reference
Antihypertensive β-lactoglobulin f (40–42) RVY Bovine (Hernández-Ledesma et al. 2004)
Antihypertensive β-lactoglobulin f 122–124) LVR Bovine (Hernández-Ledesma et al. 2004)
Antihypertensive β-casein f (60–66) YPFPGPI Bovine (Hernández-Ledesma et al. 2004
Antihypertensive β-casein f (134–138) HLPLP Bovine (Hernández-Ledesma et al. 2004)
Antihypertensive α-lactalbumin f (59–60) IW Bovine (Martin et al. 2008)
Antihypertensive β-lactoglobulin f (46–48) LKP Bovine (Català-Clariana et al. 2010)
Antihypertensive β-lactoglobulin f (142–145) ALPM Bovine (Català-Clariana et al. 2010)
Antihypertensive β-lactoglobulin f (15–20) VAGTWY Bovine (Català-Clariana et al. 2010)
Antihypertensive αs2-casein f (201–203) IPY Bovine (Català-Clariana et al. 2010)
Antihypertensive β-casein f (63–68) PGPIHNI Bovine (Català-Clariana et al. 2010)
Antihypertensive β-casein f (125–129) HLPLP Human (Hernández-Ledesma et al. 2007)
Antihypertensive β-casein f (80–90) TPVVVPPFLQP Human (Bouzerzour et al. 2012)
Antioxidant Unknown N/A YGYTGA Human (Tsopmo et al. 2011)
Antioxidant Unknown N/A ISELGW Human (Tsopmo et al. 2011)
Antioxidant β-casein f (154–160) WSVPQPK Human (Hernández-Ledesma et al. 2007)
Antithrombotic κ-casein f (114–124) IAIPPKKIQDK Human (Chabance et al. 1995)
Antithrombotic κ-casein f (106–116) MAIPPKKNQDK Bovine (Chabance et al. 1995)
Opioid β-casein f (60–66) YPFPGPI Bovine (De Noni, 2008; De Noni
and Cattaneo, 2010)
Opioid β-casein f (60–64) YPFPG Bovine (Jarmolowska et al. 2007a)
Opioid κ-casein f (25–34) YIPIQYVLSR Bovine (Jarmolowska et al. 2007a)
Opioid β-casein f (51–55) YPFVE Human (Jarmolowska et al. 2007b)
Opioid β-casein f (51–57) YPFVEPI Human (Jarmolowska et al. 2007b)
Immunomodulatory β-casein f (60–66) YPFPGPI Bovine (Bouzerzour et al. 2012)
Mineral binding αs1-casein – SpSpSpEE
(cluster sequence)
Bovine (Miquel et al. 2006; Miquel et al.
2005)
Mineral binding αs2-casein – SpSpSpEE
(cluster sequence)
Bovine (Miquel et al. 2006; Miquel et al.
2005)
Mineral binding β-casein – SpSpSpEE
(cluster sequence)
Bovine (Miquel et al. 2005)
Antimicrobial κ-casein f (106–169) – Bovine (Brück et al. 2003)
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positive impact on the unhydrolyzed samples and did not affect the hydrolyzed whey-
based formulas with respect to ACE inhibition. This suggests that whey hydrolysates
survive physiological digestion. Similar findings were reported by other researchers
(Martin et al. 2008) who compared the ACE-inhibitory activity of hypoallergenic
formulas and breast milk. The dipeptide Ile-Trp (IW), present at positions 59–60 in
bovine α-lactalbumin from hypoallergenic formulas, was identified as the most potent
ACE inhibitor in this study. According to the authors, conventional milk-based formulas
and breast milk samples did not exhibit ACE inhibition. In agreement with the previous
studies, SGID did not affect the overall inhibitory effect of the hydrolysate formula,
indicating that the peptides survive gastrointestinal hydrolysis. The presence of peptides
with potent ACE-inhibitory activity was also confirmed in more recent studies with
hypoallergenic formulas containing partially hydrolyzed whey, highly hydrolyzed whey
and casein, and highly hydrolyzed casein bovine proteins (Català-Clariana et al. 2010). In
this case, five bioactive peptides namely LKP, IPY, ALPM, PGPIHN, and VAGTWY
were detected by means of capillary electrophoresis time-of-flight mass spectrometry.
In other studies, breast milk and bovine milk protein-based infant formulas were
digested with pepsin and pancreatin and the contribution of the fragments generated to
ACE-inhibitory activity was determined (Hernández-Ledesma et al. 2007). This study
revealed that the peptide fraction obtained from human breast milk showed limited
ACE-inhibition compared with the one exhibited by the corresponding fraction obtained
from infant formulas. According to the authors, this is due to the different peptide
fragments obtained from human milk samples and infant formulas following hydrolysis
with the specific enzymes. Interestingly, only one peptide (HLPLPL) was common
between the digests of human and bovine origin. Nevertheless, a potent ACE inhibitor
was identified in human milk and corresponded to the β-casein fragment f(125–129)
with the sequence HLPLP. In this case, it was hypothesized that the presence of the
amino acid proline at the C-terminal end could be crucial in terms of the activity
observed (Cheung et al. 1980). Finally, the peptide f 80-90 (TPVVVPPFLQP) from
β-casein which is known to possess antihypertensive activities was detected in
animal models fed with infant formulas (Bouzerzour et al. 2012). In this study,
piglets were used as a model to study aspects of protein digestion and absorption in
human infants.
The production of reactive oxygen species (ROS) is part of normal cell metabo-
lism. In some cases, such as in preterm infants, high levels of ROS are produced that
disturb the redox balance and result in a state formerly known as oxidative stress
(Buonocore et al. 2002). Oxidative stress induced by free radicals is linked to the
pathogenesis of various diseases including heart disease (Aruoma 1998). The anti-
oxidant potential of human milk has been documented in the past (Friel et al. 2002).
According to Samaranayaka and Li-Chan (2011), peptides and proteins are implicated in
the overall antioxidative status of cells and contribute towards maintaining the health of
biological tissue. Recent findings indicate that peptides released from human milk after
digestion with pepsin and pancreatin could be beneficial with respect to antioxidant
activity (Tsopmo et al. 2011). In this study, the peptides YGYTGA and ISELGW
showed high radical scavenging activity, and this property was attributed to the presence
of the amino acid tryptophan which can break radical chain reactions thanks to the
donation of the hydrogen attached to the nitrogen of its indole ring. The same hypothesis
was made by other researchers who reported moderate antioxidant activity by peptides
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derived from digested human samples with pepsin and pancreatin (Hernández-Ledesma
et al. 2007). In this case, the peptide with the highest antioxidant activity was
WSVPQPK, which also contains tryptophan and, thus, may serve as hydrogen donor
and/or free radical scavenger.
Peptides of human (IAIPPKKIQDK) and bovine (MAIPPKKNQDK) origin with
antithrombotic effects were detected at physiologically active levels in the plasma of
newborn infants after breastfeeding or ingestion of cow milk-based formula (Chabance
et al. 1995). These peptides, known as κ-caseinoglycopeptides, exert their biological
function by reducing platelet aggregation and enhancing fibrinolysis, which results in the
prevention of thrombosis development.
4.2 Effects on the nervous system
Opioid peptides are small molecules which are synthesized in vivo and may function
both as hormones and neurotransmitters. These peptides depending on their bioac-
tivity are classified as opioid agonists or antagonists. β-casomorphins derived from
β-casein, and particularly β-casomorphin-5 (BCM5) and β-casomorphin-7 (BCM7),
are the best-known opioid peptides (Schlimme et al. 1989). The release of BCM7
from commercial milk-based infant formulas following SGID was confirmed (De
Noni 2008). The peptides identified were released from genetic variants A1 and B of
β-casein. According to the European Food Safety Authority, there is no established
relationship between the dietary intake of BCM7 and non-communicable diseases
(EFSA European Food Safety Authority 2009). Although no safe conclusions can be
drawn at the moment regarding the minimum amount of BCM7 capable to elicit
pharmacological effects in vivo or ex vivo, further studies confirm its release by the
action of gastrointestinal proteases during in vitro digestion in commercial infant
formulas at concentrations between 0.04 and 0.21 mg.l (De Noni and Cattaneo 2010).
The presence of four opioid peptides in the commercially available Humana formula
(Humana GmbH, Germany) for newborns after digestion with pepsin and trypsin has
been documented (Jarmolowska et al. 2007a). Both opioid agonists (BCM5) and
antagonists (casoxin C, casoxin 6, and lactoferroxin A) deriving from β-, κ-casein,
and lactoferrin were identified. All four opioid peptides were detected in the formulas
prior to enzymatic hydrolysis at concentrations between 0.075 to 0.39 μg.ml with
their concentration to rise sharply after enzyme hydrolysis. The presence of BCM5
and BCM7 in human milk has also been confirmed with the content of the opioid
peptides being dependent on the lactation stage (Jarmolowska et al. 2007b).
BCM7 and related compounds have been linked in the past with the development
of human diseases such as juvenile diabetes, heart disease, autism, and schizophrenia
(McLachlan, 2001). Although evidence regarding the abundance of such peptides in
infant formulas is inconclusive, the formation of BCMs in infant feeds following
SGID has been demonstrated. The in vivo effects of these peptides on the human
physiology have not yet been fully described.
4.3 Other health-promoting effects
It has been demonstrated that protein peptides exert biological action on the metabolism
of minerals. Minerals play a multifunctional role in human health. They participate in
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bone structure and teeth and are involved in several metabolic processes such as energy
production, nutrient absorption, protein building, and blood formation (Soetan et al.
2010). Casein phosphopeptides (CPPs) deriving from the digestion of milk proteins may
act as mineral carriers and affect their bioavailability in the human body (Meisel and
Fitzgerald 2003). Recent studies document the presence of bioactive peptides with
mineral carrier properties in infant formulas (Miquel et al. 2006). The peptides origi-
nating from αs1 and αs2-casein survived SGID with pepsin and pancreatin, and their
identified molecular masses were in the range of 1,400 to 9,600 Da, which makes them
good candidates for intestinal absorption. According to the authors, calcium could be
bound preferentially to CPPs with the cluster sequence SpSpSpEE and iron and zinc to
CPPs with the phosphorylated cluster and phosphoserine residues. The release of CPPs
with metal-chelating properties following SGID of infant formulas was also reported in
previous studies (Miquel et al. 2005). Many of these CPPs were only detected in
probiotic formulas indicating that they are formed by the action of bifidobacteria.
Dietary protein is known to play a major role in the human body's defense mechanism
against infection by either stimulating the immune system (immunomodulatory) or
contributing to the inhibition of microbial growth (antimicrobial). Supplementation of
infant formulas with α-lactalbumin and glycomacropeptide (GMP), a derivative of κ-
casein, which were digested with pepsin and pancreatin, resulted in decreased counts of
Bacteroides (Brück et al. 2003). This was attributed to the ability of the supplemented
formula to mimic the fermentative qualities of breast milk and induce the growth of
protective microflora in the gastrointestinal tract. Furthermore, the bacteriostatic and
bactericidal effects of α-lactalbumin and GMP have been demonstrated when a signif-
icant reduction in enteropathogenic bacteria including enteropathogenic Escherichia
coli and Salmonella was observed following supplementation of the infant formulas
with the specific milk substrates (Brück et al. 2003). The release of bioactive peptides
with immunomodulatory activities from infant formulas is also documented by more
recent studies. In this case, the peptide f 60-66 (YPFPGPI) from β-casein was detected
following in vivo digestion by piglets which were fed with infant formulas (Bouzerzour
et al. 2012). According to the findings of this study, whey proteins were more resistant to
enzymatic digestion in the stomach of piglets compared to caseins with the latter being
hydrolyzed to a large extent just 30 min after meal ingestion.
5 Conclusions
Extensive research has underlined the important contribution of breastfeeding in promot-
ing general health, growth, and development of the human species and the significant
reduction in the risk of acute and chronic diseases (Gartner et al. 2005). Proteins contribute
to the nutritional value of milk and also have other biological roles as intact molecules, as
many of them are resistant to the effects of digestion (Chatterton et al. 2004). On the other
hand, digestion of milk proteins in the gastrointestinal tract results in the release of
bioactive agents which may affect several physiological processes. Despite the fact that
many of these bioactive peptides have been identified as integral parts of milk proteins,
their contribution in human nutrition has not been sufficiently described in the literature.
Furthermore, limited information is available with respect to their passage through the
human, and most importantly the infant's digestive tract. Up-to-date, bioactive peptides
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have been identified in both human milk and cow milk-based infant formulas, which
differ in their amino acid profiles and properties. Modern methods of analysis enable fast
and reliable separation and identification of bioactive peptides in milk-derived products
(Català-Clariana et al. 2013). The peptides identified following SGID have antihyperten-
sive, antioxidant, antithrombotic, opioid, mineral carrier, and immunogenic effects on
human physiology. Further research in this field is required to establish the beneficial role
of human or bovine milk from that perspective. It seems likely though that peptides from
milk protein of bovine origin could be a valuable supplement to human milk. The
manufacture of “chimeric” infant formulas with multiple health-promoting effects could
be used as a model example in the future for the manufacture of ultimately functional
foods.
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